Phase 1
Completed N=41
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Source: ClinicalTrials.gov NCT03374241 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Number of Participants With Adverse Events — 3; 2; 3; 7 Participants
Summary
Single ascending dose of HM15211 in healthy obese subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events |
3; 2; 3; 7; 4; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Female subjects must be non-pregnant and non-lactating
Exclusion Criteria
- Participation in an investigational study within 30 days prior to dosing
Data sourced from ClinicalTrials.gov (NCT03374241). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.